Clinical Data ConfidenceElicio’s long term 2P Phase 1 data showed at least twice as long median recurrence-free survival compared to historical data, adding confidence to the ongoing Phase 2 trial.
Clinical Trial EnrollmentElicio has fully enrolled the Phase 2 trial in approximately 12 months, demonstrating a rapid pace of enrollment despite challenges.
Potential Commercial SuccessPotential successful commercialization of ELI-002 7P across multiple solid tumor types could yield peak revenues exceeding $550M in the U.S. alone by 2035.